Skip to content

The Use of Lactobacillus Plantarum 299v in Treatment of Cancer Patients Who Received Home Enteral Nutrition

The Use of Lactobacillus Plantarum 299v in Treatment of Cancer Patients Who Received Home Enteral Nutrition

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03940768
Enrollment
35
Registered
2019-05-07
Start date
2019-05-10
Completion date
2020-03-01
Last updated
2020-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Keywords

cancer, home enteral nutrition, probiotic, Lactobacillus plantarum 299v

Brief summary

The aim of the study is to assess the impact of Lactobacillus plantarum 299v on nutritional status, tolerance of enteral diet and the quality of life. Administration of this probiotic may potentially improve nutritional status and tolerance of enteral diet. It also may provide positive effect on quality of life.

Detailed description

Study group consists of patients with cancer who are qualified for home enteral nutrition in Nutritional Counselling Center Copernicus in Gdansk. The control group will receive home enteral nutrition and placebo. The experimental group will receive home enteral nutrition and Lactobacillus plantarum 299v. The study is prospective and double-blind. The parameters for evaluation of nutritional status are: BMI, body mass analysis, level of total protein and albumin in blood serum, total lymphocyte count, NRS 2002 method. Assessment of the quality of life and tolerance of enteral diet will be done by questionaires.

Interventions

Administration of Lactobacillus plantarum 299v in cancer patients who receive home enteral nutrition.

DIETARY_SUPPLEMENTPlacebo

Administration of placebo in cancer patients who receive home enteral nutrition.

Sponsors

Medical University of Gdansk
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* age ≥18 yr., * the presence of cancer, artificial access to the alimentary tract (naso-gastric tube, gastrostomy, percutaneous endoscopic gastrostomy, jejunostomy, microjejunostomy), * qualification for home enteral nutrition, * written consent to take part in the study

Exclusion criteria

* age \<18 yr., * patients requiring home parenteral nutrition, * patients who are not being able to attend the visit in the study centre.

Design outcomes

Primary

MeasureTime frameDescription
Changes of total lymphocyte countat baseline and after 4th weeknumber of total lymphocyte count/mm\^3
Changes of the albumin concentrationat baseline and after 4th weekalbumin concentration g/L
Changes of total protein concentrationat baseline and after 4th weektotal protein concentration g/L
Changes of fat massat baseline and after 4th weekfat mass in percent (%)
Changes of muscle massat baseline and after 4th weekmuscle mass in kilograms (kg)
Changes of total body waterat baseline and after 4th weektotal body water in percent (%)
Changes of body mass indexat baseline and after 4th weekbody mass index in kg/m\^2

Secondary

MeasureTime frameDescription
Change of patients' quality of life ( BREF - WHOQOL - Bref The World Health Organization Quality of Life)at baseline and after 4th weekQuestionare containing questions divided in 4 domains (regarding environment, psychological, somatic, social factors). Each question gets points in scale 1-5, where 1 being the worst score. Within each domain poins are summed up.
Change of enteral nutrition toleranceit will be filled every day by patients per 4 weeks treatment periodThe enteral nutrition tolerance will be assessed with authors own questionnaire referring to number of stools, frequency of vomiting and flatulence.

Countries

Poland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 26, 2026